Literature DB >> 24619141

Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment.

John M Harrold1, Anson K Abraham.   

Abstract

Practitioners of pharmacokinetic/pharmacodynamic modeling routinely employ various software packages that enable them to fit differential equation based mechanistic or empirical models to biological/pharmacological data. The availability and choice of different analytical tools, while enabling, can also pose a significant challenge in terms of both, implementation and transferability. A package has been developed that addresses these issues by creating a simple text-based format, which provides methods to reduce coding complexity and enables the modeler to describe the components of the model based on the underlying physiochemical processes. A Perl script builds the system for multiple formats (ADAPT, MATLAB, Berkeley Madonna, etc.), enabling analysis across several software packages and reducing the chance for transcription error. Workflows can then be built around this package, which can increase efficiency and model availability. As a proof of concept, tools are included that allow models constructed in this format to be run with MATLAB both at the scripting level and through a generic graphical application that can be compiled and run as a stand-alone application.

Mesh:

Year:  2014        PMID: 24619141     DOI: 10.1007/s10928-014-9352-6

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  16 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

2.  Application of PBPK modelling in drug discovery and development at Pfizer.

Authors:  Hannah M Jones; Maurice Dickins; Kuresh Youdim; James R Gosset; Neil J Attkins; Tanya L Hay; Ian K Gurrell; Y Raj Logan; Peter J Bungay; Barry C Jones; Iain B Gardner
Journal:  Xenobiotica       Date:  2011-10-30       Impact factor: 1.908

Review 3.  Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment.

Authors:  John C Lipscomb; Sami Haddad; Torka Poet; Kannan Krishnan
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 4.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

5.  The Systems Biology Markup Language (SBML): Language Specification for Level 3 Version 1 Core.

Authors:  Michael Hucka; Frank T Bergmann; Stefan Hoops; Sarah M Keating; Sven Sahle; James C Schaff; Lucian P Smith; Darren J Wilkinson
Journal:  J Integr Bioinform       Date:  2015-09-04

Review 6.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

Review 7.  Target-mediated drug disposition and dynamics.

Authors:  Donald E Mager
Journal:  Biochem Pharmacol       Date:  2006-02-15       Impact factor: 5.858

Review 8.  Merging systems biology with pharmacodynamics.

Authors:  Ravi Iyengar; Shan Zhao; Seung-Wook Chung; Donald E Mager; James M Gallo
Journal:  Sci Transl Med       Date:  2012-03-21       Impact factor: 17.956

9.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

Review 10.  Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.

Authors:  Kenneth T Luu; Eugenia Kraynov; Bing Kuang; Paolo Vicini; Wei-Zhu Zhong
Journal:  AAPS J       Date:  2013-02-14       Impact factor: 4.009

View more
  3 in total

1.  A cell-level model of pharmacodynamics-mediated drug disposition.

Authors:  Wojciech Krzyzanski; John M Harrold; Liviawati S Wu; Juan Jose Perez-Ruixo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-09       Impact factor: 2.745

2.  Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies.

Authors:  Vaishali L Chudasama; Anup Zutshi; Pratap Singh; Anson K Abraham; Donald E Mager; John M Harrold
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-01-06       Impact factor: 2.745

3.  Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.

Authors:  Vaishali L Chudasama; Meric A Ovacik; Darrell R Abernethy; Donald E Mager
Journal:  J Pharmacol Exp Ther       Date:  2015-07-10       Impact factor: 4.030

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.